彭布罗利珠单抗
封锁
前列腺癌
医学
免疫检查点
肿瘤科
前列腺
癌症
内科学
免疫疗法
受体
出处
期刊:Cancer Discovery
[American Association for Cancer Research]
日期:2023-05-04
卷期号:13 (5): 1032-1033
被引量:1
标识
DOI:10.1158/2159-8290.cd-nb2023-0017
摘要
Abstract Late-stage trials evaluating the PD-1 inhibitor pembrolizumab in men with prostate cancer have all ended in failure, leading clinicians to conclude that new treatment strategies are needed to help make checkpoint blockade more effective in the immune-suppressed environment of most prostate tumors.
科研通智能强力驱动
Strongly Powered by AbleSci AI